

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Jean E.F. Rivier et al.	
Serial No.: 10/763,935	Group Art Unit: 1654
Filed: January 22, 2004	Examiner: Hemant Khanna
Title: CRFR1 SELECTIVE LIGANDS	Confirmation No. 5057
Attorney Docket No.: 73933/5193	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO REQUEST UNDER 35 U.S.C. § 121

Dear Sir:

In the paper mailed January 11, 2007, to which a shortened statutory period for reply was set to expire on February 12, 2007, Applicants elect to prosecute claims to the cyclic peptide described in Example 1; namely, (cyclo 31-34)[Ac-Pro⁴, D-Phe¹², Nle^{21,38}, Glu³¹, Lys³⁴]-r/hCRF(4-41). It is believed that all of claims 1-10 would be readable on the elected species.

The Examiner's reference to the absence of SEQ ID identifiers and a sequence listing is noted. This absence was also noted by the PTO in the Notice to File Missing Parts. When the executed Declaration was filed, it was pointed out that, because all of the sequences contain a D-isomer, a sequence listing was not required. Following this response, the Request for a Sequence Listing was withdrawn; none should now be required.

Issuance of an Office Action on the merits at an early date is respectfully requested.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Address all correspondence to:
FITCH, EVEN, TABIN & FLANNERY
120 So. LaSalle Street, Ste. 1600
Chicago, IL 60603

/jjs/

James J. Schumann
Attorney for Applicant(s)
Reg. No. 20,856

Direct telephone inquiries to:
James J. Schumann
(858) 552-1311
San Diego, California Office of
FITCH, EVEN, TABIN & FLANNERY

Date: February 12, 2007